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Abstract
Background: Musculoskeletal (MSK) pain represents a considerable worldwide healthcare burden. This study aimed
to gain consensus from practitioners who work with MSK pain patients, on the most appropriate primary care
treatment options for subgroups of patients based on prognostic risk of persistent disabling pain. Agreement was
sought on treatment options for the five most common MSK pain presentations: back, neck, knee, shoulder and
multisite pain, across three risk subgroups: low, medium and high.
Methods: Three consensus group meetings were conducted with multi-disciplinary groups of practitioners (n = 20)
using Nominal Group Technique, a systematic approach to building consensus using structured in-person meetings
of stakeholders which follows a distinct set of stages.
Results: For all five pain presentations, “education and advice” and “simple oral and topical pain medications” were
agreed to be appropriate for all subgroups. For patients at low risk, across all five pain presentations “review by
primary care practitioner if not improving after 6 weeks” also reached consensus. Treatment options for those at
medium risk differed slightly across pain-presentations, but all included: “consider referral to physiotherapy” and
“consider referral to MSK-interface-clinic”. Treatment options for patients at high risk also varied by pain
presentation. Some of the same options were included as for patients at medium risk, and additional options
included: “opioids”; “consider referral to expert patient programme” (across all pain presentations); and “consider
referral for surgical opinion” (back, knee, neck, shoulder). “Consider referral to rheumatology” was agreed for
patients at medium and high risk who have multisite pain.
Conclusion: In addressing the current lack of robust evidence on the effectiveness of different treatment options
for MSK pain, this study generated consensus from practitioners on the most appropriate primary care treatment
options for MSK patients stratified according to prognostic risk. These findings can help inform future clinical
decision-making and also influenced the matched treatment options in a trial of stratified primary care for MSK pain
patients.
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Background
Musculoskeletal (MSK) pain represents a considerable
worldwide healthcare burden [1] and, in the UK, ac-
counts for 14% of all general practice (GP) consultations
[2]. Individual GP treatment is highly variable [3], which
may be in part due to a lack of confidence in managing
these problems [4], as well as MSK pain being given
lower priority when compared with other acute illnesses
with more medically critical symptoms [5, 6]. A key re-
sult of this variability in management is that some pa-
tients may, at least initially, receive suboptimal care
including inappropriate treatment referrals, whilst others
fail to receive appropriate early referral [7, 8].
Current usual primary care for MSK pain in the UK
commonly follows a ‘stepped, wait and see’ approach,
with patients initially given low intensity and low cost
treatments, moving onto higher intensity or more costly
treatments if needed [9]. An alternative approach is to
stratify patient care according to the patient’s risk of
poor outcome, e.g. persistent disabling pain. Stratified
primary care has been shown to be clinically and cost
effective for low back pain [10–12]. This approach
involved the use of a brief self-report tool− the STarT
Back tool [13], to identify patients’ risk of persistent
disabling pain, and matching risk subgroups (i.e. low,
medium and high risk) to appropriate first-line treat-
ment options. Using this approach, patients who need
more intensive treatment are identified at the outset,
allowing them to be ‘fast-tracked’ to that treatment,
whilst patients at low risk can be reassured of their good
prognosis and unnecessary treatments can be avoided.
The most recent UK National Institute for Health and
Care Excellence (NICE) guidelines [14] recommend risk
stratification for low back pain in primary care; for
instance, using the STarT Back Tool [13].
Given findings that similar prognostic factors predict
outcome across different body region pain sites [15], the
Stratified Primary Care for Musculoskeletal Pain
research programme is developing and testing a new
stratified care intervention for patients with the five
most common musculoskeletal pain presentations in pri-
mary care – back, neck, shoulder, knee and multisite
pain. A new prognostic tool developed and validated as
part of a linked observation cohort study (n = 1890) [16]
– the STarT MSK tool™, is used in general practice to
stratify patients as low, medium or high in relation to
risk of persistent disabling pain, with matched treatment
options recommended for each subgroup. The reason
for developing a new stratified care model is that whilst
the prognostic factors do overlap with STarT Back, it
was recognised that the matched treatments needed to
reflect the slightly different patient profiles of the STarT
MSK Tool’s low, medium and high risk subgroups, as
well the more heterogeneous population being targeted,
which requires a broader range of recommended matched
treatments, for high risk patients in particular. The clinical
effectiveness and cost-effectiveness of this approach com-
pared to usual, non-stratified care is currently being tested
in a randomised controlled trial (RCT).
This paper reports on an expert consensus groups study,
the findings of which informed the matched treatment op-
tions tested as part of the trial. The aim was to gain con-
sensus from a range of practitioners who work with MSK
pain patients on the most appropriate primary care
treatment options, in a UK National Health Service (NHS)
context, for patients consulting with the five pain presenta-
tions of interest across the three different risk subgroups,
based on prognostic risk of persistent disabling pain. Con-
sensus group methods are particularly useful in fields
where scientific evidence is uncertain or inconclusive [17].
The approach was therefore well-suited to the aims of this
study, as a systematic review conducted earlier in the
research programme revealed a lack of robust evidence on
the effectiveness of different MSK treatment options [18].
Whilst the study has a UK focus, the role of GPs and pri-
mary care physiotherapists in providing first line manage-
ment for MSK conditions is common to many countries;
therefore, findings can have wider applicability for inform-
ing practice in other non-UK settings.
Methods
Study design
This study uses a consensus groups method; an approach
commonly employed in the development of healthcare in-
terventions, due principally to their capacity to ‘harness
the insights of appropriate experts to enable decisions to
be made’ [17]. The consensus group method used in this
study is Nominal Group Technique (NGT). Originally de-
veloped by Delbecq, van de Ven and Gustafson [19], NGT
is a systematic approach to building consensus using
structured in-person meetings of experts. NGT follows a
distinct set of stages that involves participants initially
generating ideas on a particular issue or problem, which
are then individually rated by participants. Following this,
the results of these ratings are discussed within the group,
and then re-rated individually by participants, who are
given the opportunity to change their scores in light of
group discussions. This process can be repeated several
times until consensus is achieved. The threshold used to
signal an acceptable level of consensus varies across NGT
studies depending on the aims and design adopted; the
threshold we adopted is discussed later; see ‘Assessing
consensus’. NGT can be adapted, for instance through use
of a ‘pre-elicitation technique’ [20], that is, providing par-
ticipants with a summary of existing evidence to inform
their decision-making. The pre-elicitation technique was
used in this study due to the wide range of literature on
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MSK treatments (see below for further explanation). The
stages of the NGT process are described in detail below.
Participants
We invited stakeholders from a range of clinical back-
grounds, including general practice, physiotherapy,
rheumatology, orthopaedics, clinical psychology and pain
medicine (see Table 1 for participant characteristics). Par-
ticipants were identified through existing clinical and re-
search networks in the UK, and were invited via email.
Dates for the meetings were arranged at the convenience
of the practitioners. The same practitioners were invited to
all three consensus group meetings (see Results below).
Ethics
Ethical approval for the study was granted by the Keele
University Ethical Review Panel (ref: ERP319). Participa-
tion in the study was entirely voluntary. Participants’
travel expenses were reimbursed, but beyond this they
received no financial incentive for taking part. Written
consent was obtained prior to each NGT meeting.
Nominal group meetings
Three NGT meetings, each focusing on one of the three
patient risk subgroups (low, medium, high risk of per-
sistent disabling pain), were conducted between April–
May 2015. Groups were convened at Keele University.
Meeting 1 focused on agreeing matched treatment op-
tions for patients at low risk of persistent disabling pain,
for all five MSK pain presentations. Meetings 2 and 3 fo-
cused on matched treatment options for patients at high
and medium risk, respectively.
The meetings each followed the same set of stages (see
Fig. 1). First a facilitator provided a brief study overview
and outlined the aims and stages of the consensus
process. Facilitators were members of the research team
and did not participate in the group discussions. The same
facilitators were used in each meeting. Participants were
initially separated into small groups (4–6 participants with
a spread of backgrounds and expertise so as to allow for
multi-disciplinary discussions) each focusing on one or
two MSK pain presentations. Each group was tasked to
agree on the most appropriate treatment options for the
MSK pain presentation and for the risk subgroup being
considered (low, medium or high). Participants were asked
to decide on treatment options for a general adult popula-
tion based on risk of poor outcome, i.e. the patient’s likeli-
hood of experiencing persistent disabling pain. To support
this, participants were provided with: a) lists of UK NHS
evidence based treatment options, developed for each risk
subgroup across each of the five pain presentations (Fig. 2
outlines the development of these lists), and b) patient vi-
gnettes exemplifying ‘typical’ patients falling within the
relevant risk subgroup, (e.g. for meeting 1, vignettes of pa-
tients at low risk). The vignettes were developed using
data from patients stratified as low, medium and high risk
using the validated STarT MSK tool™ as part of the earlier
observational cohort study [16]. Vignettes were used as
illustrative examples to give participants information
about key characteristics of each patient subgroup in
order to inform their decision-making on appropriate
treatment options (see Table 2).
Participants first silently reviewed the resources pro-
vided in order to identify relevant treatment options they
felt were missing from the list of UK NHS evidence
based treatment options. Participants were encouraged
to focus on first-line actions that could be taken by a
GP, rather than treatment decisions made further along
the treatment pathway, e.g. specific surgical procedures.
Participants took turns to share any additional treatment
options within their small group, which were noted on a
flipchart by the facilitator. Once all additional ideas had
Table 1 Participant Characteristics: Breakdown of clinical expert participants by gender and professional background across the
three consensus group meetings
Consensus group meeting 1
(n=18)
Consensus group meeting 2
(n=16)
Consensus group meeting 3
(n=12)
Female/ Male 8/10 7/9 5/7
General Practitioners 4 4 4
Physiotherapists specialising in MSK pain 5 5 3
Rheumatologists 3 1 1
Clinical Psychologist 1 1 1
AHP (Allied Health Professionals) clinical
coordinator
1 1 1
Therapy pathway manager 1 1 1
Pain medicine consultant 1 1 0
Clinical Research Consultant 1 1 1
Spinal Surgeon 1 1 0
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Fig. 1 Stages of Nominal Group Technique (NGT): Outline of the stages followed in each of the three consensus group meetings
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been recorded, each additional treatment option gener-
ated through this initial stage (i.e. not including the
existing options on the evidence-based lists) was dis-
cussed in turn within the small groups. Those that were
agreed upon after discussion – in terms of their appro-
priateness for the given pain presentation and risk sub-
group, and those available on the NHS – were added to
the treatment options list. Participants then silently and
anonymously rated, on a 7-point Likert scale, the ap-
propriateness of each treatment option on the group’s
list for the MSK pain presentation and risk subgroup
being considered (e.g. appropriateness for patients with
shoulder pain classified at low risk). The mean appro-
priateness score was then calculated for the group for
each treatment option on the list by members of the
research team. Options were then organised in rank
order, i.e. the option with the highest mean ranked
number 1, and so on.
All participants then joined together with others for a
full group discussion of the treatment options for each
MSK pain presentation. The full group was presented
with the list of treatment options for each pain presenta-
tion in rank order. All participants then had the oppor-
tunity to ask questions and suggest further relevant
treatments they felt were missing. All suggested options
were written on a flipchart and discussed in turn by the
full group. Participants then voted via a show of hands
as to which treatment options should be added to the
Fig. 2 Deriving a priori treatment option lists: Description of the process for developing lists of UK NHS evidence based treatment options for
each risk subgroup across each of the five pain presentations prior to the consensus group meetings. These lists were used as pre-elicitation
information to inform the practitioners’ decisions
Table 2 Vignettes of patients at low, medium and high risk: Descriptions of typical patients subgrouped as low, medium and high
risk of persistent disabling pain. Vignettes were developed using data collected as part of a linked observational cohort study, and
were included to inform the practitioners about key characteristics of each patient subgroup to aid decision making in the
consensus group meetings
Low risk patient vignette: back
pain
A 61 year old lecturer visiting her GP with back pain. At the time of completing the questionnaire the pain is 7/10 but
usually 4/10 over the last couple of weeks. It is only bothering her slightly and is limiting her activities a little, but she
has been taking some over-the-counter painkillers. Rates general health as good. Not feeling anxious or depressed.
Medium risk patient vignette:
multisite pain
A 45 year-old man consulted his doctor with back, knee and shoulder pain. He rates his current pain as 7/10 and
extremely bothersome. He works fulltime as a continuous improvement specialist, and has not had to take any time
off work as a result of his pain. He has had his current pain problem for 6-9 months, and is in constant, severe pain.
The pain interferes a lot with his enjoyment of life, and his daily activities are limited a little, such as climbing the stairs
and carrying groceries. He rates his general health as poor. He feels that there is a very good chance that his pain will
be a long-term problem. He has trouble sleeping due to his pain and often feels tired and worn out. He does not feel
anxious or depressed when he thinks about his pain, and he feels completely confident that he can cope with his pain
in most situations.
High risk patient vignette:
shoulder pain
A 51 year old full-time service engineer went to his doctor with shoulder pain. He has had his pain for 1-2 years, it is
currently 10/10 and extremely bothersome. He is feeling very anxious at the moment, and worries that his pain might
become persistent. He is limited a lot in daily activities such as household chores and dressing himself. He feels tired
most of the time and is having trouble sleeping. He also has a hiatus hernia.
Protheroe et al. BMC Musculoskeletal Disorders          (2019) 20:271 Page 5 of 10
final treatment option list (those agreed by more than
half of the full group members).
Using the final list, all participants silently and an-
onymously rated, again on a 7-point Likert scale, the ap-
propriateness of each treatment option (for the MSK
pain presentation and risk subgroup). The consensus
process described above was repeated for all five MSK
pain presentations and for each risk subgroup.
Assessing consensus
Following the three group meetings, the mean scores
were calculated across all participants for each MSK
pain presentation and each risk subgroup. A list of treat-
ment options identified for each pain presentation in
each risk subgroup was compiled and sent to partici-
pants via email to consider and resolve any inconsisten-
cies and approve the finalised list of treatment options.
Through discussions within the research team, as well as
considering consensus thresholds used in previous NGT
studies reported in the research literature, it was decided
that a mean rating of > 50% signalled an acceptable
level of consensus for a treatment option to be in-
cluded in the final list. This cut-off point reflected
the challenge in gaining consensus from a multi-dis-
ciplinary group compared to a group from a single
health professional discipline [21–23]. Additionally,
we wanted the final treatment option lists to be in-
clusive so that when these are used by GPs in consul-
tations, the range of available options can allow for
patient choice and shared decision-making.
Results
Participants
In total, 20 participants attended at least one of the
three NGT meetings; however, not all participants were
able to attend all three group meetings (group 1: n = 18
participants; group 2: n = 16; group 3: n = 12). Partici-
pants had a range of clinical backgrounds, with a mix
of experience levels/ length of time in practice (2–27
years in current clinical role; mean = 12 years). They
also came from a range of geographical areas within the
UK, giving a breath of knowledge on the diversity of
existing treatments available within the NHS nationally
(see Table 3).
Matched treatment options
The following matched treatment options were agreed
and are presented in full in Table 4.
Treatment options for all risk subgroups
Two treatment options were agreed as appropriate for pa-
tients with any of the pain sites and in any risk subgroup:
“education and advice” and “simple oral and topical pain
medications limited to those available over the counter”. In
what follows we present those other options that reached
consensus for specific pain-site presentations and/or risk
subgroups.
Low risk
The following treatment option was agreed for all patients
classified as low risk: “review by primary care practitioner
if not improving after 6 weeks”. For multisite pain only, a
further matched treatment option that reached consensus
was: “refer to supported self-management and locally
available community resources e.g. walking group, exer-
cise on prescription”.
Medium risk
Seven treatment options reached consensus for low back
pain, six for multisite pain, and four each for knee pain,
neck pain and shoulder pain. For all five pain-site presenta-
tions, options included: “consider referral to physiotherapy”
and “consider referral to MSK-interface-clinic1”. “Occupa-
tional Health/work place assessment and advice” was
agreed for every pain presentation for medium risk, except
for multisite pain. In addition, “consider referral to psycho-
social intervention or multidisciplinary pain management
service” reached consensus only for back and multisite
pain. Three treatment options were agreed in relation to
one of the pain presentations only: “address comorbidities,
distress and frailty” (back); “refer to rheumatology” (multi-
site); and “corticosteroid injection” (shoulder). “Persona-
lised exercise programmes” was agreed for medium risk
back, knee and multisite pain, but not for neck or shoulder
pain. “Atypical analgesia (e.g. Amitriptyline, Pregabalin,
Gabapentin)” was agreed for medium risk back, multisite
and neck pain, but not for knee or shoulder.
High risk
Nine treatment options reached consensus for back pain,
ten for knee pain, nine for multisite pain, nine for neck
pain, and eight for shoulder pain. Six treatment options
were agreed across all five pain presentations for patients
at high risk: “consider referral to physiotherapy (all
Table 3 Geographical spread: Breakdown of clinical expert
participants by UK geographical area in which they practise
Geographical area Number of participants
North West England 4
West Midlands of England 10
South East England 1
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modalities)”; “consider referral to MSK interface clinic”;
“consider referral to psychosocial intervention or multi-
disciplinary pain management service”; “address comor-
bidities, distress and frailty”; “opioids”; and “consider
referral to expert patient programme”. “Occupational
Health/work place assessment and advice” was agreed
for patients at high risk with back, knee and neck pain,
respectively, but not for shoulder or multisite pain.
“Atypical analgesia” reached consensus for all presenta-
tions with the exception of knee. “Corticosteroid injec-
tion” reached consensus only for knee and shoulder pain
for high risk patients. “Refer for surgical opinion” was
included for all presentations for high risk except for
multisite pain; however, multisite pain was the only pres-
entation for which “refer to rheumatology” was included
for high risk. Two other treatment options were agreed
only for one of the pain presentations and none of the
others: “personalised exercise programmes” (multisite)
and “refer for lifestyle intervention e.g. dietician, slim-
ming world etc.” (knee). The full list of agreed treatment
options for all five pain presentations across the three
risk subgroups is displayed in Table 4. The results are
summarised in Table 5, below:
Discussion
This study generated an acceptable level of consensus
(which we defined as an average across all partici-
pants of > 3.5 out of 7 on a likert scale (i.e. > 50%)
for each treatment option, as discussed further
below), among a group of practitioners who work
with MSK pain patients about appropriate matched
treatment options for each of the five most common
MSK pain presentations (back, knee, shoulder, neck
and multisite pain) according to the patient’s risk of
persistent disabling pain. Seventeen treatment options
in total reached our predefined level of consensus –
four for patients at low risk, 10 for medium risk and
15 for high risk, with some variation observed in
treatment options reaching consensus across different
MSK pain presentations. It was reassuring to note
that as the risk of persistent disabling pain increased,
the suggested treatment options also increased in
both number and intensity. This would be expected
Table 5 Summary of results: Discursive summary of the agreed
treatment options across all five pain presentations and three
risk subgroups: low, medium and high
Low risk Self-management education/ advice; simple pain
medications limited to those available over the counter.
Medium
risk
In addition to options at low risk, may consider options
such as: onward referral, e.g. physiotherapy, MSK interface
clinic; or prescribing atypical analgesia.
High risk In addition to options at low and medium risk, may
consider options such as: referral to psychosocial
intervention or pain management service; refer to expert
patient programme; refer for surgical opinion; address
comorbidities, distress and frailty.
Table 4 Final agreed matched treatment options: Full list of agreed treatment options for all five pain presentations across the
three risk subgroups. Ticked boxes indicate that > 50% agreement was reached for the listed treatment option for the
corresponding risk subgroup and pain presentation
L =Low risk; M=Medium risk; H=High risk Back Knee Multisite Neck Shoulder
L M H L M H L M H L M H L M H
Education and advice, including exercise, activity modification, weight loss etc. ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Simple oral and topical pain medications limited to those available over the counter ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Review by primary care practitioner if not improving after 6 weeks ✓ ✓ ✓ ✓ ✓
Refer to physiotherapy (all modalities) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Refer to MSK interface clinic ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Refer to psychosocial intervention or pain management service ✓ ✓ ✓ ✓ ✓ ✓ ✓
Personalised exercise programmes, e.g. personal trainer if available ✓ ✓ ✓ ✓
Occupational Health/workplace advice ✓ ✓ ✓ ✓ ✓ ✓ ✓
Address comorbidities, distress and frailty ✓ ✓ ✓ ✓ ✓ ✓
Atypical analgesia (e.g. amitriptyline, pregabalin, gabapentin) ✓ ✓ ✓ ✓ ✓ ✓
Opioids ✓ ✓ ✓ ✓ ✓
Refer to supported self-management and locally available community resources e.g. walking group,
exercise on prescription
✓
Refer to expert patient programme ✓ ✓ ✓ ✓ ✓
Refer for lifestyle intervention e.g. dietician, slimming world etc. ✓
Refer for surgical opinion ✓ ✓ ✓ ✓
Corticosteroid injection ✓ ✓ ✓
Refer to Rheumatology ✓ ✓
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given that patients at higher risk will likely have more
complex needs− either due to high pain intensity,
psychological or social factors, or a combination of
these− and it is therefore appropriate for GPs to have
a range of treatment options to choose from depend-
ing on the individual needs of the patient, including
more intensive or invasive options if necessary. The
final agreed matched treatment options appear to be
both clinically appropriate and in keeping with the
risk profiles for each of the three risk subgroups.
Comparison across MSK pain presentation and risk
subgroup
The agreed treatment options for patients at low risk prin-
cipally involve GP-supported self-management, and do not
include referral for further treatment, reflecting the aim of
stratified care to avoid over-treating patients with a good
prognosis [24]. The additional treatment option agreed
only for low risk multisite pain – “refer to supported self-
management and locally available community resources
e.g. walking group, exercise on prescription” – may reflect
the additional complexity of managing pain at more than
one body region site, with the participants believing that
these patients would benefit from further support in
addition to that provided by the GP.
As well as the treatment options agreed for low risk,
medium risk included the addition of onward referral op-
tions across all five MSK pain sites: “consider referral to
physiotherapy” and “consider referral to MSK interface
clinic”. Including options for onward referral reflects the
increased need of patients at medium risk, who may ex-
perience higher levels of pain and greater functional limita-
tions compared to low risk patients. There was also some
variation in agreed treatment options for patients with dif-
ferent MSK pain-site presentations who are at medium risk
of poor outcome. For instance, “consider referral to psy-
chosocial intervention or pain management service” was
included for back and multisite pain, but not for the other
three pain sites; this may reflect the higher prevalence of
psycho-social issues associated with these pain sites, e.g.
both are strongly associated with an increased risk of devel-
oping co-morbid depression [25, 26]. Other agreed treat-
ment options that differed across pain sites included
“atypical analgesia”, which reached consensus for patients
at medium risk with back, multisite and neck pain, but not
for those with knee or shoulder pain; which is likely to re-
flect the greater prevalence of radicular pain from these
three sites. A number of guidelines suggest that atypical an-
algesia is more effective for neuropathic pain and following
discussion amongst the participants this was further simpli-
fied to being recommended for patients with radicular
pain. Two treatment options were agreed only in relation
to one of the five pain sites at medium risk: “corticosteroid
injection” (shoulder), and “refer to rheumatology”
(multisite). Again these results appear clinically appropri-
ate: administering an injection is a common first-line treat-
ment for shoulder pain; and the option to refer to
rheumatology for multisite pain patients takes into ac-
count the importance of identifying in primary care
early indications of inflammatory arthritis, in order to
reduce diagnostic delay [27].
There was some overlap in the matched treatment op-
tions that reached consensus for patients at medium and
high risk of poor outcome, although additional options
were agreed for patients at high risk across all five pain pre-
sentations. Two treatment options reached consensus for
all five MSK pain presentations for patients at high risk,
but did not reach consensus for any of the MSK pain pre-
sentations for patients at medium risk: “opioids” and “refer
to expert patient programme”. That opioids were agreed
only for patients at high risk of poor outcome reflects
current UK practice guidelines– primary care clinicians are
encouraged to prescribe non-opioid based analgesia where
possible, and only prescribe opioids for patients with high
pain levels or who have an inadequate response to
paracetamol and/or nonsteroidal anti-inflammatory drugs
[14]. The expert patient programme places focus on self-
management of long-term conditions and therefore may be
appropriate for some high risk patients given their poorer
prognosis, and subsequent higher probability of experien-
cing long-term disability. “Refer for surgical opinion”
reached consensus only for patients at high risk, for all
MSK pain sites except multisite pain; whilst “refer to
rheumatology” was agreed for patients with multisite pain
only. This again reflects the different perspectives from this
group of practitioners about how best to manage multisite
pain – and particularly widespread pain – in comparison to
single site pain. “Corticosteroid injection” reached consen-
sus for patients with knee and shoulder pain at high risk,
but not for patients with MSK pain at the other three sites;
again reflecting common practice of injecting peripheral
joints [28]. “Refer for lifestyle intervention e.g. dietician,
slimming world etc.” reached consensus only for patients at
high risk with knee pain and not for any of the other four
pain presentations. This reflects the evidence base re-
garding the association between obesity and knee
joint pain [29] and the functional difficulties resulting
from knee pain that can hinder patients’ efforts to en-
gage in physical activity.
Strengths and limitations
This study innovatively combined NGT with pre-elicitation
techniques of patient vignettes derived from epidemio-
logical data and supported by a rigorous review of the avail-
able best evidence [18] (see Fig. 2). The multidisciplinary
nature of the sample of participants was also an important
strength as this allowed access to a varied range of expertise
in the field of MSK pain. It was felt that this would lead to
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less restricted results than might have been found had the
participants been made up of GPs alone. Whilst this repre-
sents a strength of the study, including a wide range of cli-
nicians made it necessary to use a lower threshold to
determine consensus than might have been the case if the
group comprised clinicians from a single discipline, who
may have more homogenous views towards treatment [22].
The > 50% cut-off point used for signalling agreement may
be viewed as a limitation of the study. However, our aim
was not to identify the single ‘best’ treatments that would
be appropriate for all patients in a given risk subgroup, but
to identify a suite of treatment options that can be recom-
mended to GPs, so that when these options are used in
consultations as part of the new stratified care model, this
can allow for professional and patient shared decision-mak-
ing. Patients stratified into the same subgroup may have
different treatment needs despite having similar risk pro-
files, and certain matched treatment options may be more
or less appropriate for an individual patient; therefore, a
high threshold for signalling agreement would not have
been appropriate. Using a higher threshold, e.g. > 75%,
would have resulted in fewer recommended treatment
options. Taking high risk knee pain as an example using
a > 75% cut off, in addition to the two generic treatments
agreed across all three risk subgroups, only two further
treatment options would have gained consensus: “consider
referral to physiotherapy”, and “consider referral to MSK
interface clinic”. The other eight treatment options would
have been excluded; similar findings regarding the restrict-
ive nature of using a higher consensus threshold are
reported in previous NGT studies [30, 31]. The decision to
use a > 50% cut-off was further reinforced through
agreement from the study participants as to the suit-
ability of the final treatment options which were sent to
them via email following the consensus group meetings
(see Methods, above).
The UK focus of the study represents both a strength
and weakness. Whilst the geographical spread of partici-
pants enabled us to produce a list of recommended treat-
ment options that is likely to have good representativeness
across the UK, the applicability beyond the UK depends
on treatment availability in other settings. However, the
majority of treatment options that reached consensus are
not UK-specific; therefore, findings can have wider applic-
ability beyond the UK context and may be useful for
informing research and practice in other settings.
A limitation is that the use of a consensus group
methodology resulted in the exclusion of newer or less
widely used treatment options. However, as previously
mentioned, we included a wide range of clinicians to
avoid missing any treatment options considered to be
best practice, even if not always supported by available
evidence. It was not considered to be appropriate to rec-
ommend untested treatment options; these treatment
options would require further research and testing. A
further limitation of this study is that we did not include
patient representatives in our expert groups. Whilst we
recognise that expert patients would have valuable input
for decisions about treatment options, it was felt that
this study was specifically about clinical expertise and
therefore was limited to clinician input. Extensive
patient representation has been included in the broader
research programme [6], and the development and test-
ing of the stratified primary care intervention.
Conclusion
A group of multi-disciplinary practitioners generated con-
sensus about appropriate matched treatment options for
risk subgroups of primary care MSK pain patients (at low,
medium and high risk of persistent disabling pain). This
information informed the matched treatment options in a
trial of stratified primary care for patients with MSK pain.
The results can also be helpful for clinicians and patients
to support greater consistency in the management of
MSK pain, addressing the issue highlighted earlier that
current variability in management can lead to some pa-
tients, at least initially, receiving suboptimal care including
inappropriate treatment referrals. Supporting greater
consistency in management can help ensure the right
patient receives the right treatment at the right time.
Endnotes
1MSK Interface Clinics are a multi-professional service
for patients with non-inflammatory and non-surgical
MSK disease, at the interface between primary and sec-
ondary care. Clinicians aim to assess and diagnose MSK
problems and agree a management plan in conjunction
with the patient. Patients can be referred to interface
clinics by general practitioners and physiotherapists.
Acknowledgements
The authors would like to thank the study participants, as well as the wider
STarT MSK programme grant team.
Funding
This paper presents independent research funded by the National Institute
for Health Research (NIHR) under its Programme Grants for Applied Research
scheme (grant number: RP-PG-1211-20010) and the Arthritis Research UK
Centre in Primary Care grant (Grant Number 18139). NF is supported through
an NIHR Research Professorship (NIHR-RP-011-015) and is a NIHR Senior In-
vestigator. CDM is funded by the NIHR Collaborations for Leadership in Ap-
plied Health Research and Care West Midlands, the NIHR School for Primary
Care Research and a NIHR Research Professorship in General Practice (NIHR-
RP-2014-04-026). EH is a NIHR Senior Investigator. The views expressed in this
publication are those of the authors and not necessarily those of the NHS,
the NIHR or the Department of Health and Social Care.
Availability of data and materials
In line with the Standard Operating Procedures in place at the Research
Institute for Primary Care and Health Sciences, where this study was
conducted, data is archived at a dedicated location within the Keele CTU
network. A request to access archived data can be made by completion of a
Data Transfer Request form, which can be accessed by contacting the RI
Protheroe et al. BMC Musculoskeletal Disorders          (2019) 20:271 Page 9 of 10
directly: Research Institute for Primary Care and Health Sciences, Keele
University, Staffordshire, ST5 5BG; Tel: + 44 (0) 1782 733905.
Authors’ contributions
JP, BS, BB, NEF, ST designed the study. JP, BS, BB, KMD, PC, VC, NEF, ST
collected the data. JP, BS, BB, JH, VC, NEF, JCH, KMD, ST were involved in
data interpretation, and analysis. JP and BS developed the first draft of the
manuscript. All authors contributed to the interpretation of the results and
critical revision of the manuscript for important intellectual content. All
authors have read and approved the final manuscript.
Ethics approval and consent to participate
Ethical approval for the study was granted by the Keele University Ethical





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Primary Care Centre Versus Arthritis, Research Institute for Primary Care &
Health Sciences, Keele University, Staffordshire ST5 5BG, UK. 2Lee Kong Chian
School of Medicine, Nanyang Technological University, 50 Nanyang Ave,
Singapore 63979, Singapore. 3Keele Clinical Trials Unit (CTU), David
Weatherall Building, Keele University, Staffordshire ST5 5BG, UK.
Received: 15 February 2019 Accepted: 24 April 2019
References
1. Vos T, Allen C, Arora M, Amare AT, Lalloo R, et al. Global, regional, and
national incidence, prevalence, and years lived with disability for 310
diseases and injuries, 1990–2015: a systematic analysis for the global burden
of disease study 2015. Lancet. 2016;388:1545–602.
2. Jordan K, Kadam U, Hayward R, Porcheret M, Young C, Croft P. Annual
consultation prevalence of regional musculoskeletal problems in primary
care: an observational study. BMC Musculoskelet Disord. 2010;11:144.
3. Maserejian NN, Fischer MA, Trachtenberg FL, Yu J, Marceau LD, McKinlay JB,
Katz JN. Variations among primary care physicians in exercise advice,
imaging, and analgesics for musculoskeletal pain: results from a factorial
experiment 2014. Arthritis Care Res. 2014;66:1:147–56.
4. Darlow B, Dean S, Perry M, Mathiesond F, Baxter GD, Dowell A. Acute low
back pain management in general practice: uncertainty and conflicting
certainties. Fam Pract. 2014;31(6):723–32.
5. Alami S, Boutron I, Desjeux D, Hirschhorn M, Meric G, Rannou F, Poiraudeau
S. Patients’ and practitioners’ views of knee osteoarthritis and its
management: a qualitative interview study. PLoS One. 2011;6(5):e19634.
6. Saunders B, Bartlam B, Foster NE, Hill JC, Cooper V, Protheroe J. General
practitioners’ and patients’ perceptions towards stratified care: a theory
informed investigation. BMC Fam Pract. 2016;17:125.
7. Buchbinder R, Staples MP, Shanahan EM, Roos JF. General practitioner
Management of Shoulder Pain in comparison with rheumatologist
expectation of care and best evidence: an Australian National Survey. PLoS
One. 2013;8(4):e61243.
8. Cottrell E, Roddy E, Rathod T, Porcheret M, Foster NE. What influences
general practitioners’ use of exercise for patients with chronic knee pain?
Results from a national survey. BMC Fam Pract. 2016;17:172.
9. Foster NE, Hill JC, O’Sullivan P, Hancock M. Stratified models of care. Best
Pract Res Clin Rheumatol. 2013;27:649–61.
10. Hill JC, Whitehurst DG, Lewis M, Bryan S, Dunn KM, Foster NE, Konstantinou
K, Main CJ, Mason E, Somerville S, Sowden G, Vohora K, Hay EM.
Comparison of stratified primary care management for low Back pain with
current best practice (STarT Back): a randomised controlled trial. Lancet.
2011;378(9802):1560–71.
11. Foster NE, Mullis R, Hill JC, Lewis M, Whitehurst DG, Doyle C, Konstantinou
K, Main CJ, Somerville S, Sowden G, Wathall S, Young J, Hay EM. Effect of
stratified care for low Back pain in family practice (IMPaCT Back): a
prospective population-based sequential comparison. Ann Fam Med. 2014;
12(2):102–11.
12. Whitehurst DG, Bryan S, Lewis M, Hay EM, Mullis R, Foster NE. Implementing
stratified primary care management for low back pain: cost-utility analysis
alongside a prospective, population-based, sequential comparison study.
Spine. 2015;40(6):405–14.
13. Hill JC, Dunn KM, Lewis M, Mullis R, Main CJ, Foster NE, Hay EM. A primary
care back pain screening tool: identifying patient subgroups for initial
treatment. Arthritis Care Res. 2008;59(5):632–41.
14. NICE (National Institute for Health and Care Excellence) Guidance. https://
www.nice.org.uk/guidance/conditions-and-diseases/musculoskeletal-
conditions. Accessed 14 Apr 2018.
15. Green DJ, Lewis M, Mansell G, Artus M, Dziedzic KS, Hay EM, Foster NE, van
der Windt DA. Clinical course and prognostic factors across different
musculoskeletal pain sites: a secondary analysis of individual patient data
from randomised clinical trials. Eur J Pain. 2018;22:1057–70.
16. Campbell P, Hill JC, Protheroe J, Afolabi E, Lewis M, et al. Keele aches and
pains study protocol: validity, acceptability and feasibility of the Keele STarT
MSK tool for subgrouping musculoskeletal patients in primary care. J Pain
Res. 2016;9:807–18.
17. Jones J, Hunter G. Consensus methods for medical and health services
research. BMJ. 1995;311:376–80.
18. Babatunde OO, Jordan JL, Van der Windt DA, Hill JC, Foster NE, Protheroe J.
Effective treatment options for musculoskeletal pain in primary care: a
systematic overview of current evidence. PLoS One. 2017;12(6):e0178621.
19. Delbecq AL, van de Ven AH, Gustafson DH. Group techniques for problem
planning. Glenview: Scott-Foresman; 1975.
20. Gonzales CK, Leroy G. Eliciting user requirements using appreciative inquiry.
Empir Softw Eng. 2011;16:733–72.
21. Leape LL, Hilborne LH, Kahan JP, Stason WB, Park RE, Kamberg CJ. Coronary
artery bypass graft: a literature review and ratings of appropriateness and
necessity. RAND. RAND/AMCC Report JRA-02; 1992.
22. Coulter I, Adams A, Shekelle P. Impact of varying panel membership on
ratings of appropriateness in consensus panels: a comparison of a multi-
and single disciplinary panel. HSR. 1995;30:4.
23. Murphy MK, Sanderson CBD, Black NA, Askham J, Lamping DL, Marteau T,
McKee CM. Consensus development methods, and their use in clinical
guideline development. Health Technol Assess. 1998;2:1–88.
24. Hingorani AD, van der Windt DA, Riley RD, Abrams K, Moons KGM.
Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ.
2013;346:e5793.
25. Bener A, Verjee M, Dafeeah EE, Falah O, Al-Juhaishi T, Schlogl J, Sedeeq A,
Khan S. Psychological factors: anxiety, depression, and somatization
symptoms in low back pain patients. J Pain Res. 2013;6:95–101.
26. Crofford LJ. Psychological aspects of chronic musculoskeletal pain. Best
Pract Res Clin Rheumatol. 2015;29:147–55.
27. Villeneuve E, Nam JL, Bell MJ, Deighton CM, Felson DT, et al. A systematic
literature review of strategies promoting early referral and reducing delays
in the diagnosis and management of inflammatory arthritis. Ann Rheum
Dis. 2013;72:1.
28. Artus M, van der Windt DA, Afolabi EK, Buchbinder R, Chesterton LS, Hall A,
Roddy E, Foster NE. Management of shoulder pain by UK general
practitioners (GPs): a national survey. BMJ Open. 2017;7(6):e015711.
29. Okifuji A, Hare BD. The association between chronic pain and obesity. J Pain
Res. 2015;8:399–408.
30. Naylor CD, Basinski A, Baigrie RS, Goldman BS, Lomas J. Placing patients in
the queue for coronary revascularization: evidence for practice variations
from an expert panel process. Am J Publ Health. 1990;80:1246–52.
31. Rubin G, De Wit N, Meineche-Schmidt V, Seifert B, Hall N, Hungin P. The
diagnosis of IBS in primary care: consensus development using nominal
group technique. Fam Pract. 2006;23:687–92.
Protheroe et al. BMC Musculoskeletal Disorders          (2019) 20:271 Page 10 of 10
